Malignant Mixed Mullerian Tumor  >>  Erbitux (cetuximab)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Erbitux (cetuximab) / Eli Lilly, EMD Serono
NCT00392769: Cetuximab in Patients With Progressive or Recurrent Endometrial Cancer

Completed
2
33
US
Cetuximab, C225, Erbitux™, IMC-C225
M.D. Anderson Cancer Center, Bristol-Myers Squibb
Endometrial Cancer
12/10
12/10

Download Options